Cash round sets up trial of InteRNA’s microRNA for cancer
financing, gene silencing, immuno-oncology, InteRNA Technologies, microRNA, Oncology, solid tumour
0 Comment
solid tumour
Exicure lists on Nasdaq, raising $55m for cancer, neurology push
Exicure, immuno-oncology, rna therapeutics, solid tumour
0 Comment
Novartis’ severe aplastic anaemia drug fast-tracked by FDA
blood disorder, cancer, Novartis, Priority Review, Promacta, SAA, severe aplastic anaemia, solid tumour
0 Comment
The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.